ABP 206 is an investigational medication being studied for its effectiveness in treating patients with melanoma that cannot be surgically removed or has spread to other parts of the body. This medication is being compared to an existing treatment to see how well it works in patients who have not received any previous systemic treatment for their advanced melanoma.

Opdivo (Nivolumab) is a medication already used in the treatment of melanoma. It works by helping the immune system to recognize and attack cancer cells. In this study, it serves as a comparison to evaluate the effectiveness and safety of the investigational medication ABP 206 in patients with advanced melanoma.

Unresectable or Metastatic Melanoma – This is a type of skin cancer that has spread beyond the original site and cannot be removed through surgery. It often begins in the melanocytes, which are the cells responsible for producing melanin, the pigment that gives skin its color. As the disease progresses, it can spread to other parts of the body, including the lymph nodes, lungs, liver, brain, and bones. The spread of melanoma to distant sites is referred to as metastasis, which can complicate treatment and management. Symptoms may include changes in existing moles, the appearance of new pigmented or unusual-looking growths on the skin, and, in advanced stages, symptoms related to the affected organs. Early detection and monitoring of skin changes are crucial in managing the progression of this disease.